Cargando…

Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older

PURPOSE: To evaluate the survival benefit of radiotherapy (RT) in esophageal cancer (EC) patients aged ≥ 80. MATERIALS AND METHODS: Records for all EC patients aged ≥ 65 years were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test compared the characteristic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shan, Zheng, Shuyu, Gong, Tuotuo, Ma, Hongbing, Ke, Yue, Zhao, Songchuan, Wang, Wenyu, Jia, Lijun, Zhang, Xiaozhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762382/
https://www.ncbi.nlm.nih.gov/pubmed/29340114
http://dx.doi.org/10.18632/oncotarget.22884
_version_ 1783291676960227328
author Huang, Shan
Zheng, Shuyu
Gong, Tuotuo
Ma, Hongbing
Ke, Yue
Zhao, Songchuan
Wang, Wenyu
Jia, Lijun
Zhang, Xiaozhi
author_facet Huang, Shan
Zheng, Shuyu
Gong, Tuotuo
Ma, Hongbing
Ke, Yue
Zhao, Songchuan
Wang, Wenyu
Jia, Lijun
Zhang, Xiaozhi
author_sort Huang, Shan
collection PubMed
description PURPOSE: To evaluate the survival benefit of radiotherapy (RT) in esophageal cancer (EC) patients aged ≥ 80. MATERIALS AND METHODS: Records for all EC patients aged ≥ 65 years were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test compared the characteristic and treatment between patients aged ≥ 80 with those aged 65–79. Focusing on patients aged ≥ 80, we employed multivariable logistic regression to identify the association between selection of RT and patients’ characteristics. Survival curve was employed to visualize the survival rate and multivariable Cox proportional hazard model was established to quantify the effect of RT on overall survival (OS) and cancer special survival (CSS). RESULTS: Patients aged ≥ 80 were more likely to be white male and have localized EC (all P < 0.001). Selection of RT in patients aged ≥ 80 were associated with cancer histology (P < 0.001), grade (P = 0.024) and stage (P < 0.001). RT significantly improved the OS (hazard ratio(HR) = 0.717) and CSS (HR = 0.722) (all P < 0.001). Further stratified analysis found the improvement were only significant in the localized (OS HR = 0.662; CSS HR=0.652) and regional stage patients (OS HR = 0.571; CSS HR = 0.581) (all P < 0.001). CONCLUSIONS: Our study suggested EC patients aged ≥ 80 benefit from RT only if the cancer is in localized/regional stage.
format Online
Article
Text
id pubmed-5762382
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57623822018-01-16 Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older Huang, Shan Zheng, Shuyu Gong, Tuotuo Ma, Hongbing Ke, Yue Zhao, Songchuan Wang, Wenyu Jia, Lijun Zhang, Xiaozhi Oncotarget Clinical Research Paper PURPOSE: To evaluate the survival benefit of radiotherapy (RT) in esophageal cancer (EC) patients aged ≥ 80. MATERIALS AND METHODS: Records for all EC patients aged ≥ 65 years were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test compared the characteristic and treatment between patients aged ≥ 80 with those aged 65–79. Focusing on patients aged ≥ 80, we employed multivariable logistic regression to identify the association between selection of RT and patients’ characteristics. Survival curve was employed to visualize the survival rate and multivariable Cox proportional hazard model was established to quantify the effect of RT on overall survival (OS) and cancer special survival (CSS). RESULTS: Patients aged ≥ 80 were more likely to be white male and have localized EC (all P < 0.001). Selection of RT in patients aged ≥ 80 were associated with cancer histology (P < 0.001), grade (P = 0.024) and stage (P < 0.001). RT significantly improved the OS (hazard ratio(HR) = 0.717) and CSS (HR = 0.722) (all P < 0.001). Further stratified analysis found the improvement were only significant in the localized (OS HR = 0.662; CSS HR=0.652) and regional stage patients (OS HR = 0.571; CSS HR = 0.581) (all P < 0.001). CONCLUSIONS: Our study suggested EC patients aged ≥ 80 benefit from RT only if the cancer is in localized/regional stage. Impact Journals LLC 2017-12-04 /pmc/articles/PMC5762382/ /pubmed/29340114 http://dx.doi.org/10.18632/oncotarget.22884 Text en Copyright: © 2017 Huang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Huang, Shan
Zheng, Shuyu
Gong, Tuotuo
Ma, Hongbing
Ke, Yue
Zhao, Songchuan
Wang, Wenyu
Jia, Lijun
Zhang, Xiaozhi
Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
title Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
title_full Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
title_fullStr Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
title_full_unstemmed Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
title_short Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
title_sort survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762382/
https://www.ncbi.nlm.nih.gov/pubmed/29340114
http://dx.doi.org/10.18632/oncotarget.22884
work_keys_str_mv AT huangshan survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT zhengshuyu survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT gongtuotuo survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT mahongbing survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT keyue survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT zhaosongchuan survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT wangwenyu survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT jialijun survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder
AT zhangxiaozhi survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder